Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018

MEBO Gut Microbiome Study
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups

Full details :
want listed ? contact
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Friday, March 26, 2010

New FMO3 paper : A physiological role for flavin-containing monooxygenase (FMO3) in humans?

Flavin mono oxygenase 3 enzyme seems to be very much the ignored xenobiotic enzyme in medical research, despite dealing with probably thousands of substrates in humans, usually oxidizing soft-nucleophilic heteroatom compounds containing sulfur, nitrogen, or phosphorous to non-toxic excretable oxides. There seem to be few researchers interested, and fewer research papers. Someday the pharmaceutical industry will realize it may be a factor in drug metabolism, as can likely be taken for granted by the amount of TMAU people who anticipate bad reactions to drugs. Currently the only 'downside' of having poor FMO3 function is regarded as trimethylaminuira, so it is likely that without our own actions, it will not be until the pharmaceutical industry realizes the 'drug metabolism' factor that frequent serious research will be done into this enzyme.

One of the 'pioneers' in FMO3 research has been Dr Stephen Mitchell of London, who did most of his FMO3 papers in the late 80's and 90's. He also seemed to have a role in organizing the 1st TMAU workshop in 1999.

He has not published an FMO3 paper for most of the last decade, but recently published a new FMO3 paper along with RL Smith, who also has a history in FMO3 research (again, not recently).

The paper is entitled :
A physiological role for flavin-containing monooxygenase (FMO3) in humans?

Unfortunately for us there is not even an abstract available to the public, so we cannot get a summary of what the paper is about. If anyone has access, it would be interesting to know more.


Post a Comment